Cancer cell-derived IL-1β reverses chemo-immunotherapy resistance in non-small cell lung cancer

Abstract Many non-small cell lung cancer (NSCLC) patients remain unresponsive to the current standard of care, which includes chemotherapy and immune checkpoint inhibitors, like anti-PD-1/PD-L1 antibodies. While interleukin (IL)-1β is known to promote lung cancer growth in humans and mice, we show h...

Descrición completa

Detalles Bibliográficos

Principais autores:	Anaïs Perrichet, Julie Lecuelle, Emeric Limagne, Marie Thiefin, Hélène Bellio, Pierre Jacob, Romain Aucagne, Aziza Aznague, Pauline Russo, Flavie Gaucher, Nicolas Roussot, Xingping Yang, Thibault Vernet, Lisa Nuttin, Alis Ilie, David Rageot, Valentin Derangère, Titouan Huppe, Alfred Zippelius, Bertrand Routy, Caroline Truntzer, Fanny Chalmin, François Ghiringhelli, Cédric Rébé
Formato:	Artigo
Idioma:	Inglês
Publicado:	Nature Portfolio 2025-11-01
Series:	Nature Communications
Acceso en liña:	https://doi.org/10.1038/s41467-025-64839-4
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!